Study shows which early stage ... avoid chemo

cp418 · February 2013

http://www.newswise.com/articles/study-shows-half-of-early-stage-breast-cancer-patients-may-safely-avoid-chemotherapy

gpawelski · February 2013

According to Johns Hopkins' Dr. Antonio C. Wolff, the excitement surrounding this whole field is such that he suspects many clinicians see the molecular assays as being superior to standard clinicopathologic data in their predictive information. He stressed that this actually hasn't been shown to be the case to date. Molecular profiling doesn't trump standard pathology. And a study published in Breast has found that while Mammaprint and other assays have been repeatedly demonstrated to provide robust prognostic information, evidence for their worth as a predictive marker for chemotherapy benefit is yet to come from randomized clinical trials and therefore its utility is limited to prognostication.

http://cancerfocus.org/forum/showthread.php?t=3859

riverhorse · February 2013

I think the press release is a bit misleading. I had the mamma print and it came back low risk but "borderline". I called Agendia to find out what that meant and was told that there was a chance the "lowrisk" result I got might not be accurate. My Oncotype result was 25. I elected to forego chemo based on my original pathology report and Cancer Math. So my insurance company paid about 8k for two ambiguous results. Like Dr Wolff I think there is a great future for these tests, but as of now they were not that helpful for me.

Study shows which early stage ... avoid chemo

Comments

Categories